Quectel Unveils Next Generation SG885G-WF Android Smart Module Ideal for High-Performance Industrial and Consumer IoT Applications
24.7.2023 12:00:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today launches its new generation flagship Android smart module, the SG885G-WF. With high performance and rich media functions, the smart module is ideal for industrial and consumer applications that require high processing power and multimedia functions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230724716405/en/
Quectel unveils next generation SG885G-WF Android smart module ideal for high-performance industrial and consumer IoT applications. (Photo: Business Wire)
The module is powered by the Qualcomm® QCS8550 System-on-Chip (SoC) for IoT from Qualcomm Technologies, Inc., delivering an impressive combination of flexibility and performance. It supports Wi-Fi 7, Bluetooth 5.3, and incorporates 2x2 Wi-Fi MIMO technology, providing users with enhanced connectivity options.
“Qualcomm Technologies is proud to collaborate with Quectel on their SG885G-WF to bring high performance connectivity solutions to consumers,” stated Dev Singh, Vice President, Business Development, Qualcomm Technologies, Inc. “Utilizing Quectel’s extensive infrastructure of cellular modules, the SG855G-WF exemplifies the necessary capabilities needed to adapt to tomorrow’s technology in IoT and beyond.”
With computing power of up to 48 TOPS, the module offers robust video capabilities, including video encoding at 4K at 120 fps or 8K at 30 fps, as well as video decoding at 4K at 240 fps or 8K at 60 fps. This ensures smooth and high-quality video processing for various applications.
Measuring 49.0mm x 51.0mm x 4.25mm, the SG885G-WF is suitable for global deployments and offers 12 GB LPDDR5X plus 256GB UFS memory. In addition, the module offers a rich set of interfaces that include LCM, camera, I2S, PCIe, UART, USB, I2C and SPI. These, in addition to adoption of the Android operating system, extend the module’s applicability to wide range of IoT and M2M applications including videoconferencing systems, live streaming devices, gaming, computing, robots, drones, AR/VR, intelligent retail and safety.
Quectel provides a range of high-performance antennas that greatly enhance wireless connectivity, aiming to assist customers in streamlining their design processes. By combining Quectel's antennas with the SG885G-WF Android Smart module, IoT developers can effectively reduce both time-to-market and costs associated with their IoT devices.
Moreover, the module offers the advantage of seamless integration with Quectel's range of cellular modules, enhancing connectivity, flexibility, and integration possibilities even further.
“We’re proud to launch our new flagship Android smart module with the new generation Quectel SG885G-WF,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “The powerful Qualcomm chipset along with support for Wi-Fi 7, Bluetooth 5.3 and 2x2 MIMO technology provides customers with a powerful module that offers connectivity choice and a wide variety of interfaces. As IoT matures, the ability to enable applications that need high processing power for AI and multimedia functions has become essential and the SG885G-WF has been designed to meet these needs.”
The Quectel SG885G-WF also offers three high-current flash LED drivers which support both flash and torch modes in addition to charging management capability which supports battery voltage detection, fuel gauge and battery temperature detection. Audio interfaces include SWR, digital microphone, MI2S and HIFI I2S.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230724716405/en/
Contact information
Media: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom